Abstract
The development of efficacious treatments targeting Alzheimer’s disease (AD) aetiology has been proved an extensive, time consuming task. Currently prescribed therapies, primarily acetylcholinesterase inhibitors such as donepezil and the NMDAreceptor antagonist memantine, concentrate on the improvement of symptoms such as cognitive decline and memory loss, however, do not address the underlying pathology of the condition. More recently, efforts have focused on developing drugs that target the hallmarks of AD, amyloid-β (Aβ) plaques and hyperphosphorylated tau tangles. Many clinical trials focusing on the removal of these proteins are presently ongoing, primarily exploring immunotherapeutic avenues such as the antibody aducanumab (targeting Aβ) and the vaccine AADvac-1 (targeting tau). However, the incomplete understanding of AD progression presents a challenge, and further studies focusing on the development of the disease are essential to the expansion of novel, efficient therapeutic routes.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Bioscience Horizons: The International Journal of Student Research
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.